VBIZF (Viva Biotech Holdings) Total Inventories : $31.1 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Total Inventories?

Viva Biotech Holdings's total inventories for the quarter that ended in Jun. 2024 was $31.1 Mil. Viva Biotech Holdings's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Jun. 2024 was $33.7 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Viva Biotech Holdings's Net-Net Working Capital per share for the quarter that ended in Jun. 2024 was $-0.12.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Viva Biotech Holdings's Days Inventory for the six months ended in Jun. 2024 was 69.48.

Inventory Turnover measures how fast the company turns over its inventory within a year. Viva Biotech Holdings's Inventory Turnover for the quarter that ended in Jun. 2024 was 2.63.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Viva Biotech Holdings's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.25.

Viva Biotech Holdings Total Inventories Historical Data

The historical data trend for Viva Biotech Holdings's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Total Inventories Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Inventories

Get a 7-Day Free Trial

25.19

36.38

46.77

36.37

37.46

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Inventories	Get a 7-Day Free Trial											46.77	38.75	36.37	31.08	37.46

Viva Biotech Holdings Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Viva Biotech Holdings (OTCPK:VBIZF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Viva Biotech Holdings's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2024 is

	Net-Net Working Capital Per Share (Q: Jun. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(142.781	+	0.75 * 60.669	+	0.5 * 31.084	-	465.686
-	0	-	1.792)	/	2141.766
=	-0.12

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Viva Biotech Holdings's Days Inventory for the six months ended in Jun. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2024 )	/	Cost of Goods Sold (Q: Jun. 2024 )	*	Days in Period
	=	33.7285	/	88.588	*	365 / 2
	=	69.48

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Viva Biotech Holdings's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2024 )	/	Average Total Inventories (Q: Jun. 2024 )
	=	88.588	/	33.7285
	=	2.63

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Viva Biotech Holdings's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	33.7285	/	135.336
	=	0.25

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Viva Biotech Holdings Total Inventories Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (OTCPK:VBIZF) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

01873:Hong Kong VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.